LPCN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LPCN is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks a strong technical entry, has no fresh positive news, and the most recent catalyst was negative trial data that led to lower analyst targets and a downgrade. With no AI Stock Picker or SwingMax signal active, this is not the kind of setup to buy immediately.
Technically, LPCN is weak and remains below key moving averages, with a bearish alignment of SMA_200 > SMA_20 > SMA_5. The MACD histogram is positive but contracting, which suggests momentum is fading rather than strengthening. RSI_6 at 41.19 is neutral and does not indicate an oversold bounce strong enough to justify an immediate buy. Price at 2.33 is below the pivot at 2.368 and near support at 2.276, with resistance at 2.46 and 2.516. Overall trend is bearish to neutral, not a strong long-term entry.
Alliance Global still keeps a Buy rating and believes the company may have a path to redo the postpartum depression trial in a reasonable timeframe. The stock may also benefit if management presents a clear development reset or new clinical plan. However, these are potential future catalysts rather than confirmed near-term positives.
The biggest negative catalyst is that oral brexanolone for postpartum depression failed to show a statistically significant reduction versus placebo at 60 hours, missing the primary endpoint. H.C. Wainwright downgraded the stock to Neutral after the Phase 3 efficacy miss. There has been no recent news in the past week, and hedge fund and insider activity are neutral. The pre-market backdrop is also weak with the S&P 500 down 0.94%.
No financial snapshot was available because of a data error, so latest-quarter revenue or growth trends cannot be verified from the provided information.
Analyst sentiment is mixed but turning more cautious. Alliance Global cut its target to $6 from $11 while still keeping Buy, arguing the failed trial may be a trial issue rather than a failed compound. H.C. Wainwright downgraded LPCN to Neutral after the Phase 3 miss, reflecting uncertainty in development progress. Earlier, Alliance Global had raised its target to $11 on optimism around approval odds and lower dilution. Net view: pros still see optionality, but the cons now dominate because the key clinical catalyst disappointed.
